Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ACP1 | P24666 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NNMT | P40261 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.51 |
| ▸ | RHOC | P08134 | 3/20 | 0.51 |
| ▸ | RHOA | P61586 | 3/20 | 0.51 |
| ▸ | JUN | P05412 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013181 | 0.90 | LMNA (0.54) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL25797243 | 0.89 | LMNA (0.53) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL22387603 | 0.89 | MAPT (0.53) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL11738143 | 0.88 | LMNA (0.59) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL18763045 | 0.87 | NNMT (0.57) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL11438532 | 0.86 | MAPT (0.58) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL965028 | 0.83 | MAPT (0.70) | LMNAALDH1A1MAPT | |
| SCHEMBL10750113 | 0.81 | LMNA (0.65) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL14263848 | 0.81 | ALDH1A1 (0.65) | LMNAACP1ALDH1A1TACR1MAPT | |
| SCHEMBL4008934 | 0.81 | EPHX2 (0.63) | LMNAALDH1A1MAPTRHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | ADIONICS (FR) | 2026-05-12 | — | — | US | disclosed |
| CN-113292128-B | Apparatus and method for desalting water by thermal deionization and liquid phase ion extraction | 艾迪奥尼克斯公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230382775-A1 | METHOD FOR EXTRACTING SALTS AND TEMPERATURE-REGENERATED EXTRACTING COMPOSITION | ADIONICS (FR) | 2023-11-30 | — | — | US | disclosed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-11772997-B2 | Method for extracting salts and temperature-regenerated extracting composition | ADIONICS (FR) | 2023-10-03 | — | — | US | disclosed |
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | ADIONICS (FR) | 2023-08-22 | — | — | US | disclosed |
| WO-2023125751-A1 | DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD | 北京大学 | 2023-07-06 | — | — | WO | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-109641160-B | Method for extracting salt and temperature-regenerated extraction composition | 艾迪奥尼克斯公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3247677-B1 | LIQUID ORGANIC COMPOSITION FOR ION EXTRACTION IN LIQUID PHASE | ADIONICS (FR) | 2021-12-08 | — | — | EP | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | LMNA 2366/4885ACP1 3703/4885ALDH1A1 3805/4885 |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | LMNA 1798/4885ACP1 1014/4885ALDH1A1 2798/4885 |
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | AQP3, AQP1, AQP4 | LMNA 1748/4885ACP1 2948/4885ALDH1A1 3499/4885 |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LMNA 3822/4885ACP1 2711/4885ALDH1A1 2105/4885 |
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | POLQ, NONO, AQP3 | LMNA 1141/4885ACP1 688/4885ALDH1A1 3793/4885 |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | CACNA1A, CACNA1I, TRPV1 | LMNA 1564/4885ACP1 4411/4885ALDH1A1 1627/4885 |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | DDT, ACHE, AHR | LMNA 3407/4885ACP1 162/4885ALDH1A1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.